MAIA Biotechnology’s THIO-101 Part C Shows 90.5% Disease Control Rate
MAIA•MAIA reports a 90.5% disease control rate (19 of 21 patients) with ateganosine plus cemiplimab in its Phase 2 THIO-101 Part C third-line NSCLC trial expansion. All patients had prior docetaxel, immunotherapy and chemotherapy resistance, compared with typical 25–35% control rates for standard third-line chemotherapy.
1. Part C Efficacy Results
The Phase 2 THIO-101 Part C expansion reported a 90.5% disease control rate, with 19 of 21 evaluable NSCLC patients showing at least stable disease after treatment with ateganosine followed by cemiplimab in 21-day cycles.
2. Heavily Pre-Treated Patient Cohort
All enrolled patients previously received docetaxel and demonstrated resistance to both immunotherapy and other chemotherapies, representing a more treatment-exhausted population than in earlier trial parts.
3. Treatment Protocol
Patients received low-dose ateganosine to induce telomere-targeted DNA damage and immune activation, followed by PD-(L)1 inhibitor cemiplimab, aiming to enhance and prolong antitumor response.
4. Safety and Enrollment Status
International enrollment in Part C is complete and the regimen has shown an acceptable safety profile to date, supporting continued evaluation of ateganosine’s potential as a third-line NSCLC therapy.
